Insider Selling: Fractyl Health, Inc. (NASDAQ:GUTS) Insider Sells 65,000 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 65,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $2.90, for a total transaction of $188,500.00. Following the completion of the transaction, the insider now owns 30,484 shares of the company’s stock, valued at $88,403.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Fractyl Health Price Performance

Shares of NASDAQ:GUTS traded down $0.07 during mid-day trading on Friday, reaching $2.79. 162,533 shares of the company’s stock were exchanged, compared to its average volume of 299,180. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.46 and a quick ratio of 7.46. Fractyl Health, Inc. has a twelve month low of $1.74 and a twelve month high of $14.50. The business’s fifty day moving average price is $3.35 and its 200-day moving average price is $5.57.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.10. The company had revenue of $0.04 million during the quarter. As a group, equities research analysts forecast that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Large investors have recently modified their holdings of the company. Rhumbline Advisers acquired a new stake in Fractyl Health during the 2nd quarter worth about $32,000. Renaissance Technologies LLC acquired a new stake in Fractyl Health during the second quarter worth approximately $61,000. Massachusetts Financial Services Co. MA increased its holdings in Fractyl Health by 2.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock worth $4,255,000 after purchasing an additional 25,829 shares in the last quarter. American International Group Inc. acquired a new position in Fractyl Health in the first quarter valued at approximately $9,911,000. Finally, M28 Capital Management LP bought a new position in shares of Fractyl Health during the 1st quarter worth approximately $13,735,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.